Research Library › Bioregulators & Thymic
Epitalon (also spelled epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, modeled on epithalamin, a peptide extract of cattle pineal glands. It was developed by Russian gerontologist Vladimir Khavinson, who filed a patent on it in 1999. As of 22 Oct 2026 it is not FDA-approved; FDA advisers voted 7-4 in July 2026 to allow compounding, and FDA has not issued a final decision.
Key facts
| Type | Synthetic tetrapeptide (four amino acids) |
|---|---|
| Sequence | Ala-Glu-Asp-Gly (AEDG) |
| Derived from | Modeled on epithalamin, a cattle pineal-gland extract |
| First described | Patent priority 1999 (FDA's 2026 briefing also cites the late 1980s) |
| Developed by | Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology |
| Regulatory status (Oct 2026) | Not FDA-approved; PCAC voted 7-4 for compounding in July 2026; no final FDA decision |
Who developed it
Epitalon was developed under Vladimir Khavinson, a Russian gerontologist who worked at the Kirov Military Medical Academy in Leningrad and in 1992 founded the St. Petersburg Institute of Bioregulation and Gerontology [1, 2]. Khavinson filed the tetrapeptide patent in 1999; the U.S. version was granted in 2004 [3]. He died in January 2024 [4].
Most published research on epitalon came from Khavinson’s own institute and collaborators [2].
Structure and proposed target
The starting point was epithalamin, a peptide extract of cattle pineal glands that entered the research literature in 1973. Researchers analyzed the extract’s amino acid composition and synthesized a single four-residue chain, Ala-Glu-Asp-Gly. FDA regards this synthetic analog as a substance distinct from the extract [2, 5].
Proposed targets in the literature are the pineal gland and telomerase, the enzyme that extends the protective ends of chromosomes. These remain proposed mechanisms; published pineal studies disagree, and none is established in people [5]. In 2025 a Brunel University London group published a cell-line study of telomere length and telomerase activity in cultured human cells [6].
Why it was created
Epitalon was created within Khavinson’s gerontology research program. His patent framed the tetrapeptide as a candidate “geroprotective” compound and proposed that it acts through antioxidant pathways and melatonin production [3]. These were the inventor’s hypotheses, not established findings.
Research timeline
- 1973: Epithalamin, the parent extract, enters the research literature [5]
- 1992: Khavinson founds the St. Petersburg Institute of Bioregulation and Gerontology [1]
- 1999: Tetrapeptide patent filed [3]
- 2004: U.S. Patent 6,727,227 granted [3]
- 2025: Brunel University London cell-line study published [6]
- Apr 2026: FDA announces removal from the Category 2 list [7]
- 24 Jul 2026: PCAC votes 7-4 for compounding [8, 9]
FDA’s 2026 briefing document gives two origin dates, “the late 1980s” in one place and 1999 in another [2].
Regulatory status as of October 2026
As of 22 Oct 2026, epitalon is not FDA-approved, and no verified approval exists elsewhere. In April 2026 FDA said it would take epitalon off its Category 2 list of bulk substances that raise significant safety concerns for compounding [7].
On 24 Jul 2026 FDA’s Pharmacy Compounding Advisory Committee voted 7-4, with one abstention, to add epitalon to the 503A bulks list, contrary to FDA staff’s recommendation [8, 9, 10]. FDA’s briefing reported no clinical data supporting its safety and no published efficacy studies for the use it reviewed [2, 11]. The vote is advisory; FDA had not issued a final decision as of 22 Oct 2026 [10]. On 14 Oct 2026 FDA sent an interim access policy on compounding certain peptides to the White House for review; its text is not public [12].
Epitalon is not named on the World Anti-Doping Agency’s 2026 Prohibited List [13].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who invented epitalon?
Epitalon was developed by Russian gerontologist Vladimir Khavinson, who filed the tetrapeptide patent in 1999.
Is epitalon FDA approved?
No. As of October 2026 it is not FDA-approved. FDA advisers voted 7-4 in July 2026 to allow compounding, but FDA has not made a final decision.
What is the amino acid sequence of epitalon?
Epitalon is the tetrapeptide Ala-Glu-Asp-Gly (alanine, glutamic acid, aspartic acid, glycine).
Is epitalon the same as epithalamin?
No. Epithalamin is a peptide extract of cattle pineal glands; epitalon is a single synthetic tetrapeptide modeled on it, and FDA regards them as different substances.
Who was Vladimir Khavinson?
Vladimir Khavinson (1946-2024) was a Russian gerontologist and military physician who led the development of thymalin, epitalon and other short peptides he called bioregulators.
Sources
- Khavinson VKh. Curriculum vitae. khavinson.info (official personal site). Link
- FDA. Briefing document: epitalon-related bulk drug substances (epitalon free base and epitalon acetate). Pharmacy Compounding Advisory Committee, 24 Jul 2026. Link
- Khavinson VK. Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application. US Patent 6,727,227 B1 (priority 11 May 1999; granted 27 Apr 2004). Link
- Barkalova E. He promised to extend the lives… (obituary of Vladimir Khavinson). Paper (Bumaga), 24 Jan 2024. Link
- Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L. Overview of epitalon – highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci. 2025;26(6):2691. doi:10.3390/ijms26062691. Link
- Al-dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. doi:10.1007/s10522-025-10315-x. Link
- Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 "do not compound" list. 16 Apr 2026. Link
- Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
- McDermott Will & Schulte. Bulk list bound? PCAC backs majority of peptides in two-day public meeting. 27 Jul 2026. Link
- Buchanan Ingersoll & Rooney. FDA advisory committee voted yes on six peptides. Now what? The regulatory road ahead. 18 Aug 2026. Link
- Eglovitch JS. FDA advisory committee backs two more peptides, rejects one for compounding list. Regulatory Focus (RAPS), 24 Jul 2026. Link
- Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
- World Anti-Doping Agency. 2026 Prohibited List. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
